Ascletis Pharma (ASCLF) News Today $0.24 0.00 (0.00%) As of 01/17/2025 Add Compare Share Share Headlines Stock AnalysisChartHeadlines All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Ascletis Pharma’s ASC30 oral tablet shows promise in obesity trialJanuary 21 at 1:30 PM | finance.yahoo.comAscletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program UpdateJanuary 21 at 6:00 AM | prnewswire.comAscletis Pharma Proposes New Incentive Schemes to Attract TalentJanuary 14, 2025 | tipranks.comAscletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical ModelDecember 18, 2024 | prnewswire.comAscletis Pharma Inc.: Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of AcneNovember 12, 2024 | finanznachrichten.deAscletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of ObesityNovember 7, 2024 | prnewswire.comAscletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of ObesitySeptember 17, 2024 | prnewswire.comChina Shineway Pharmaceutical Group Ltd 02877July 26, 2024 | morningstar.comModerate to Severe Acne Pipeline Landscape Analysis, 2024, Featuring Emerging Therapies ASC40 (Ascletis Pharma), BTX 1503 (Botanix Pharmaceuticals), and MoreJune 6, 2024 | globenewswire.comAscletis Announces Strategic Decisions on FXR agonist ASC42April 3, 2024 | prnewswire.comAscletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual MeetingMarch 10, 2024 | prnewswire.comWeek In Review: Arrivent BioPharma Raises $175M In IPO For In-Licensings From ChinaJanuary 28, 2024 | seekingalpha.comAscletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of AcneJanuary 24, 2024 | finance.yahoo.comGannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASHJanuary 23, 2024 | finance.yahoo.comGannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic SteatohepatitisJanuary 2, 2024 | finance.yahoo.comAscletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of AcneDecember 5, 2023 | finance.yahoo.comAscletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHBNovember 12, 2023 | finance.yahoo.comDr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023November 8, 2023 | finance.yahoo.comGannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&DNovember 6, 2023 | finance.yahoo.comAscletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional CureSeptember 28, 2023 | finance.yahoo.comAscletis enrols all patients in trial of glioblastoma therapySeptember 26, 2023 | msn.comAscletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent GlioblastomaSeptember 26, 2023 | finance.yahoo.comClinical Results of ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection Presented at the 12th IAS Conference on HIV ScienceJuly 24, 2023 | prnewswire.comAscletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023June 26, 2023 | finance.yahoo.comAscletis Pharma: China Approves To Conduct Phase IIa Clinical Trial For ASC10 To Treat RSV InfectionMay 8, 2023 | markets.businessinsider.comAscletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus InfectionMay 8, 2023 | finance.yahoo.comAscletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for AcneMay 2, 2023 | finance.yahoo.comAscletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech IndexFebruary 27, 2023 | finance.yahoo.comAscletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus InfectionJanuary 31, 2023 | finance.yahoo.comAscletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China NMPAJanuary 26, 2023 | finance.yahoo.comSupply enters ritonavir tablets supply agreement with SimcereJanuary 17, 2023 | msn.comAscletis Announces Entering into a Supply Agreement of Ritonavir Tablets with SimcereJanuary 16, 2023 | finance.yahoo.comAscletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19January 15, 2023 | finance.yahoo.comViking Therapeutics sues Ascletis Pharma for stealing trade secretsJanuary 3, 2023 | msn.comAscletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as PlannedDecember 20, 2022 | finance.yahoo.comAscletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its DerivativesDecember 19, 2022 | finance.yahoo.comAscletis Announces Positive Early-Stage Results Of Oral RdRp Inhibitor ASC10 For COVID-19December 12, 2022 | markets.businessinsider.comAscletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19December 12, 2022 | finance.yahoo.comAscletis Pharma Shares Gain After Covid-19 Drug Approved for Clinical TrialDecember 7, 2022 | marketwatch.comAscletis Pharma Announces IND Approval For ASC11 In China - Quick FactsDecember 7, 2022 | markets.businessinsider.comAscletis gets Chinese drug regulator nod to start trial of oral COVID therapyDecember 7, 2022 | seekingalpha.comAscletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for AcneNovember 30, 2022 | finance.yahoo.comAscletis Pharma : FDA Approves IND Of Oral 3CLpro Inhibitor ASC11 For COVID-19November 23, 2022 | markets.businessinsider.comAscletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDANovember 23, 2022 | finance.yahoo.comAscletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPANovember 16, 2022 | finance.yahoo.comAscletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19November 1, 2022 | finance.yahoo.comAscletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox IndicationOctober 26, 2022 | finance.yahoo.comWeek In Review: AIM Vaccine Stages $20 Million IPO On Hong Kong ExchangeOctober 10, 2022 | seekingalpha.comAscletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19October 10, 2022 | finance.yahoo.comAscletis Announces Dosing of the First Patient in Phase II Clinical Trial of THRβ Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASHOctober 4, 2022 | finance.yahoo.com Get Ascletis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ASCLF and its competitors with MarketBeat's FREE daily newsletter. Email Address ASCLF Media Mentions By Week ASCLF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASCLF News Sentiment▼0.770.64▲Average Medical News Sentiment ASCLF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASCLF Articles This Week▼20▲ASCLF Articles Average Week Get Ascletis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ASCLF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Algernon Pharmaceuticals News Today ALK-Abelló A/S News Today Alpha Tau Medical News Today Apollomics News Today Arno Therapeutics News Today Ascentage Pharma Group International News Today Avacta Group News Today Awakn Life Sciences News Today AXIM Biotechnologies News Today BerGenBio ASA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ASCLF) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascletis Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascletis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ASCLF Stock Alerts